Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
L 60 vin, gi 1.340.000 VND
Retatrutide is a triple receptor agonist developed by Eli Lilly, simultaneously targeting GLP-1R, GIPR, and GCGR a combination not seen in any currently approved medicine
Research peptides referenced on PeptideStack are intended for in-vitro laboratory research only and are not presented as treatments, prescriptions, or instructions for human use
Diabetes Obes Metab 25(6):15031511
When interpreted with clinical assessment and biomarker data, these insights can support a more personalized conversation with your provider about whether tirzepatide, semaglutide, or a dual-compound approach may be most appropriate for your situation
US$ 26.95
US$ 28.92
US$ 27.82
